{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:23:48Z","timestamp":1790936628066,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1995,2,1]],"date-time":"1995-02-01T00:00:00Z","timestamp":791596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Nuerosci"],"published-print":{"date-parts":[[1995,2]]},"DOI":"10.1007\/bf02190411","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T00:36:21Z","timestamp":1127262981000},"page":"320-324","source":"Crossref","is-referenced-by-count":46,"title":["Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs"],"prefix":"10.1007","volume":"244","author":[{"given":"K.","family":"Ikeguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02190411_CR1","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-III)","author":"American Psychiatric Association","year":"1980","unstructured":"American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders (DSM-III). American Psychiatric Association; Washington, DC"},{"key":"BF02190411_CR2","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-III-R)","author":"American Psychiatric Association","year":"1987","unstructured":"American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd edn, revised. American Psychiatric Association, Washington, DC","edition":"3rd edn, revise"},{"key":"BF02190411_CR3","first-page":"383","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"RJ Baldessarini","year":"1990","unstructured":"Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's the pharmacological basis of therapeutics, Pergamon Press, New York, pp 383\u2013435"},{"key":"BF02190411_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archneur.1980.00500520053008","volume":"37","author":"BL Beasley","year":"1980","unstructured":"Beasley BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37:155\u2013156","journal-title":"Arch Neurol"},{"key":"BF02190411_CR5","first-page":"492","volume":"40","author":"G Bersani","year":"1986","unstructured":"Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40:492\u2013499","journal-title":"Curr Ther Res"},{"issue":"Suppl","key":"BF02190411_CR6","first-page":"163","volume":"14","author":"W Birkmayer","year":"1978","unstructured":"Birkmayer W (1978) Toxic delirium afterl-dopa medication. J Neural Transm (Suppl) 14:163\u2013166","journal-title":"J Neural Transm"},{"key":"BF02190411_CR7","first-page":"24","volume-title":"Meyler's side effects of drugs","author":"B Blackwell","year":"1984","unstructured":"Blackwell B (1984) Antidepressant drugs. In: Dukes MNG (ed) Meyler's side effects of drugs, 10th edn. Excerpta Medica, Amsterdam, pp 24\u201361","edition":"10th edn."},{"key":"BF02190411_CR8","first-page":"1352","volume":"146","author":"RH Bouchard","year":"1989","unstructured":"Bouchard RH, Pourchur E, Vincent P (1989) Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146:1352\u20131353","journal-title":"Am J Psychiatry"},{"key":"BF02190411_CR9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003495-197816040-00001","volume":"16","author":"RN Brogden","year":"1978","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS (1978) Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 16:273\u2013301","journal-title":"Drugs"},{"key":"BF02190411_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archneur.1970.00480270003001","volume":"23","author":"GG Celesia","year":"1970","unstructured":"Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestatitions of levodopa therapy. Arch Neurol 23:193\u2013200","journal-title":"Arch Neurol"},{"key":"BF02190411_CR11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0140-6736(70)92837-0","volume":"2","author":"TN Chase","year":"1970","unstructured":"Chase TN (1970) 5-Hydroxytryptophan in parkinsonism. Lancet 2: 1029\u20131030","journal-title":"Lancet"},{"key":"BF02190411_CR12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.22.5.479","volume":"22","author":"TN Chase","year":"1972","unstructured":"Chase TN, Ng LKY, Watanabe AM (1972) Parkinson's disease. Modification by 5-hydroxytryptophan Neurology 22:479\u2013484","journal-title":"Neurology"},{"key":"BF02190411_CR13","first-page":"427","volume":"41","author":"AC Declerck","year":"1987","unstructured":"Declerck AC, Wauquier A, Van Der Ham-Veltman, Gelders Y (1987) Increase in slow-wave sleep in humans with the serotonin-S2 antagonist ritanserin. Curr Ther Res 41:427\u2013432","journal-title":"Curr Ther Res"},{"key":"BF02190411_CR14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/jnnp.45.12.1161","volume":"45","author":"Y Smet De","year":"1982","unstructured":"De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45:1161\u20131164","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02190411_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.163.4.451","volume":"163","author":"SJ Duinkerke","year":"1993","unstructured":"Duinkerke SJ, Botter PA, Jansen AAI, Van Dongen PAM, Van Haaften AJ, Boom AJ, Van Laarhoven JH, Busard HLSM (1993) Ritanserin, a selective 5-HT2\/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled doubleblind trial. Br J Psychiatry 163:451\u2013455","journal-title":"Br J Psychiatry"},{"key":"BF02190411_CR16","first-page":"153","volume-title":"Recent developments in Parkinson's disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RL, UPDRS Development Committee (1987) United Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. McMillian Health Information, Florham Park, New York, pp 153\u2013163"},{"key":"BF02190411_CR17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2165\/00003495-199040050-00007","volume":"40","author":"A Fitton","year":"1990","unstructured":"Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 40: 722\u2013747","journal-title":"Drugs"},{"key":"BF02190411_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0028-1107783","volume":"99","author":"W Gehlen","year":"1974","unstructured":"Gehlen W, M\u00fcller J (1974) Zur Therapie der Dopa-Psychosen mitl-Tryptophan. Dtsch Med Wochenschr 99:457\u2013463","journal-title":"Dtsch Med Wochenschr"},{"key":"BF02190411_CR19","first-page":"325","volume":"9","author":"Y Gelders","year":"1986","unstructured":"Gelders Y, YandenBusshe G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in treatment of chronic schizophrenia. Clin Neuropharmacol 9:325\u2013327","journal-title":"Clin Neuropharmacol"},{"key":"BF02190411_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","volume":"91","author":"RA Glenonn","year":"1983","unstructured":"Glenonn RA, Young R, Rosecrans JA (1983) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pahrmacol 91:189\u2013196","journal-title":"Eur J Pahrmacol"},{"key":"BF02190411_CR21","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505\u20132511","journal-title":"Life Sci"},{"issue":"Suppl 2","key":"BF02190411_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000212588","volume":"28","author":"CG Gottfries","year":"1982","unstructured":"Gottfries CG, Br\u00e5ne G, Steen G (1982) A new rating scale for dementia syndromes. Gerontology 28 (Suppl 2):20\u201331","journal-title":"Gerontology"},{"key":"BF02190411_CR23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427\u2013442","journal-title":"Neurology"},{"key":"BF02190411_CR24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0006-8993(86)90299-4","volume":"378","author":"C Idzikowski","year":"1986","unstructured":"Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2 antagonist increases human slow-wave sleep. Brain Res 378: 146\u2013148","journal-title":"Brain Res"},{"key":"BF02190411_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00310523","volume":"88","author":"S Korsgaard","year":"1986","unstructured":"Korsgaard S, Friis T (1986) Effects of mianserin in neuroleptic-induced parkinsonism. Psychopharmacology 88:101\u2013111","journal-title":"Psychopharmacology"},{"key":"BF02190411_CR26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.0954-6820.1973.tb19428.x","volume":"194","author":"J Lehmann","year":"1973","unstructured":"Lehmann J (1973) Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effects of tryptophan on mental disturbances. Acta Med Scand 194:181\u2013189","journal-title":"Acta Med Scand"},{"key":"BF02190411_CR27","first-page":"594","volume":"12","author":"D Lukoff","year":"1986","unstructured":"Lukoff D, Neuchterlein KH, Ventura J (1986) Manual for expanded brief psychiatric rating scale (BPRS). Schizophr Bull 12:594\u2013602","journal-title":"Schizophr Bull"},{"key":"BF02190411_CR28","first-page":"587","volume":"43","author":"HY Meltzer","year":"1991","unstructured":"Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587\u2013604","journal-title":"Pharmacol Rev"},{"key":"BF02190411_CR29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2183\/pjab.57.351","volume":"57(B)","author":"H Narabayashi","year":"1981","unstructured":"Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T (1981)l-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc Jpn Acad 57(B):351\u2013354","journal-title":"Proc Jpn Acad"},{"key":"BF02190411_CR30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00216069","volume":"96","author":"T Paiva","year":"1988","unstructured":"Paiva T, Arriaga F, Wauquier A (1988) Effects of ritanserin on sleep disturbances of dysthymic patients. Psychopharmacology 96:395\u2013399","journal-title":"Psychopharmacology"},{"key":"BF02190411_CR31","first-page":"303","volume-title":"Psychopharmacology: the third generation of progress","author":"SJ Peroutka","year":"1987","unstructured":"Peroutka SJ (1987) Serotonin receptors. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 303\u2013311"},{"issue":"Suppl 3","key":"BF02190411_CR32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/S0007125000297274","volume":"153","author":"MJ Schmidt","year":"1988","unstructured":"Schmidt MJ, Fuller RW, Wong DT (1988) Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br J Psychiatry 153 (Suppl 3):40\u201346","journal-title":"Br J Psychiatry"},{"key":"BF02190411_CR33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00380972","volume":"235","author":"E Scholz","year":"1985","unstructured":"Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 235:60\u201364","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"BF02190411_CR34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/15563657709046281","volume":"10","author":"P Schuster","year":"1977","unstructured":"Schuster P, Gabriel E, Kufferle B, Stobl G, Karobath M (1977) Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 10:437\u2013441","journal-title":"Clin Toxicol"},{"key":"BF02190411_CR35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.43.1_Part_1.211","volume":"43","author":"EN Steur","year":"1993","unstructured":"Steur EN (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43:211\u2013213","journal-title":"Neurology"},{"key":"BF02190411_CR36","first-page":"399","volume":"146","author":"JL Tate","year":"1989","unstructured":"Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperiodol and fluoxetine. Am J Psychiatry 146:399\u2013400","journal-title":"Am J Psychiatry"},{"key":"BF02190411_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0165-1781(88)90037-6","volume":"23","author":"PT Trepacz","year":"1988","unstructured":"Trepacz PT, Baker RW, Greenhouse J (1988) A symptom rating scale for delirium. Psychiatry Res 23:89\u201397","journal-title":"Psychiatry Res"},{"key":"BF02190411_CR38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"HH Tol Van","year":"1991","unstructured":"Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610\u2013614","journal-title":"Nature"},{"key":"BF02190411_CR39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","volume":"40","author":"EC Wolters","year":"1990","unstructured":"Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R, Calne S, Calne DB (1990) Clozapine in the treatment of parkinsonian patients with dopaminergic psychosis. Neurology 40:832\u2013834","journal-title":"Neurology"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02190411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02190411\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02190411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T13:33:37Z","timestamp":1557840817000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02190411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,2]]}},"alternative-id":["BF02190411"],"URL":"https:\/\/doi.org\/10.1007\/bf02190411","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2]]}}}